1. New Data in nAMD: What Does the Future Hold?

2. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Evolving Treatment Paradigms in nAMD

5. Current Anti-VEGF Therapy for nAMD: Benefits and Limitations

6. Unmet Needs of Anti-VEGF Therapy

7. Future Considerations in nAMD Treatment

8. New Treatments in Development

9. Molecular Characteristics of Brolucizumab

10. Molecular Sizes of Anti-VEGF Agents

11. Single-Chain Variable Fragment

12. Potential Clinical Implications of Molecular Characteristics of Brolucizumab

13. Clinical Relevance of Brolucizumab Trial Designs

14. HAWK and HARRIER Trial Design

15. HAWK and HARRIER Trial Design: Matched Comparison Phase

16. Potential Clinical Relevance of Study Design

17. Clinical Trial Results: HAWK and HARRIER

18. HAWK and HARRIER Trial Design

19. Proportion of Patients Maintaining Every 12 Week Dosing of Brolucizumab at 48 Weeks

20. Central Subfield Thickness

21. Relevance of Clinical Trial Results

22. Emerging Therapies in nAMD Treatment

23. Designed Ankyrin Repeat Protein (DARPin®): Abicipar Pegol

24. Abicipar Pegol: REACH Phase 2 Clinical Study Visual Acuity Results

25. Angiopoietins as a Target in nAMD: Nesvacumab

26. Squalamine Eyedrops

27. Gene Therapy in nAMD

28. Gene Therapy in nAMD: Therapeutic Aim

29. Impact of New Agents on Clinical Practice

30. Improvements in Outcomes: Advances to Reduce Treatment Burden

31. Clinical Trials of Brolucizumab: Reduction in Anatomic Thickness With a Less Frequent Injection Frequency

32. BCVA Change From Baseline Over Time

33. Other Agents and Approaches in the Pipeline

34. Abbreviations

35. Abbreviations (cont)